Patricia Ann Duffy

Array ( [id] => 14213991 [patent_doc_number] => 20190119380 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-25 [patent_title] => FUNCTIONAL PLASTICITY OF ILC2, IMMUNITY, AND COPD [patent_app_type] => utility [patent_app_number] => 16/094938 [patent_app_country] => US [patent_app_date] => 2017-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17233 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16094938 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14342183 [patent_doc_number] => 20190153064 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-23 [patent_title] => COMPOSITIONS AND METHODS OF CHIMERIC ALLOANTIGEN RECEPTOR T CELLS [patent_app_type] => utility [patent_app_number] => 16/093539 [patent_app_country] => US [patent_app_date] => 2017-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21496 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16093539 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17713653 [patent_doc_number] => 11377637 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-05 [patent_title] => Transgenic T cell and chimeric antigen receptor T cell compositions and related methods [patent_app_type] => utility [patent_app_number] => 16/091494 [patent_app_country] => US [patent_app_date] => 2017-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 89 [patent_figures_cnt] => 99 [patent_no_of_words] => 64152 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16091494 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14375235 [patent_doc_number] => 20190161530 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-30 [patent_title] => CHIMERIC ANTIGEN RECEPTOR T CELL COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 16/092146 [patent_app_country] => US [patent_app_date] => 2017-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39270 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -73 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16092146 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14105137 [patent_doc_number] => 20190094244 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-28 [patent_title] => Free Functional Annexin Levels in Plasma as a Biomarker of Cardiovascular Risk [patent_app_type] => utility [patent_app_number] => 16/087183 [patent_app_country] => US [patent_app_date] => 2017-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11617 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16087183 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14072387 [patent_doc_number] => 20190085081 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-21 [patent_title] => CHIMERIC ANTIGEN RECEPTOR [patent_app_type] => utility [patent_app_number] => 16/085189 [patent_app_country] => US [patent_app_date] => 2017-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52580 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -59 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16085189 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17407188 [patent_doc_number] => 11248057 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-15 [patent_title] => CD20 binding single domain antibodies [patent_app_type] => utility [patent_app_number] => 16/082300 [patent_app_country] => US [patent_app_date] => 2017-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 24 [patent_no_of_words] => 39274 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16082300 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14029575 [patent_doc_number] => 10226520 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-03-12 [patent_title] => Compositions and methods for enterohemorrhagic [patent_app_type] => utility [patent_app_number] => 15/436044 [patent_app_country] => US [patent_app_date] => 2017-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 15108 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15436044 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14372371 [patent_doc_number] => 20190160098 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-30 [patent_title] => CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/077937 [patent_app_country] => US [patent_app_date] => 2017-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15858 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16077937 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17378169 [patent_doc_number] => 11236166 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-01 [patent_title] => CD8 binding agents [patent_app_type] => utility [patent_app_number] => 16/075317 [patent_app_country] => US [patent_app_date] => 2017-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 10 [patent_no_of_words] => 43434 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16075317 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13870719 [patent_doc_number] => 20190031700 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-31 [patent_title] => Modified hexa-acylated neisserial LPS [patent_app_type] => utility [patent_app_number] => 16/072895 [patent_app_country] => US [patent_app_date] => 2017-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20911 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16072895 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13870849 [patent_doc_number] => 20190031765 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-31 [patent_title] => COMBINATION OF AN OX40 AGONIST AND A 4-1BB AGONIST MONOCLONAL ANTIBODY FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 16/069712 [patent_app_country] => US [patent_app_date] => 2017-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19599 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16069712 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16800221 [patent_doc_number] => 10995142 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-04 [patent_title] => Monoclonal antibody FnAb8 and application thereof [patent_app_type] => utility [patent_app_number] => 16/069423 [patent_app_country] => US [patent_app_date] => 2017-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 6 [patent_no_of_words] => 9095 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 198 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16069423 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13826537 [patent_doc_number] => 20190016753 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-17 [patent_title] => METHODS FOR SEPARATING ISOFORMS OF MONOCLONAL ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/067196 [patent_app_country] => US [patent_app_date] => 2017-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6519 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 213 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16067196 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16998401 [patent_doc_number] => 11077183 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-03 [patent_title] => CD40 ligand fusion protein vaccine [patent_app_type] => utility [patent_app_number] => 15/393543 [patent_app_country] => US [patent_app_date] => 2016-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 23763 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15393543 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13777969 [patent_doc_number] => 20190002523 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-03 [patent_title] => T CELL RECEPTORS SPECIFIC FOR THE NY-ESO-1 TUMOR ANTIGEN-HLA-A*02 COMPLEX [patent_app_type] => utility [patent_app_number] => 16/065047 [patent_app_country] => US [patent_app_date] => 2016-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13026 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16065047 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11757554 [patent_doc_number] => 20170204423 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-20 [patent_title] => 'Methods of Transforming a Listeria' [patent_app_type] => utility [patent_app_number] => 15/379257 [patent_app_country] => US [patent_app_date] => 2016-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 11537 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15379257 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13622225 [patent_doc_number] => 20180362664 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR TREATING HEREDITARY ANGIOEDEMA ATTACK [patent_app_type] => utility [patent_app_number] => 16/061103 [patent_app_country] => US [patent_app_date] => 2016-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24508 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -57 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16061103 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17541036 [patent_doc_number] => 11306147 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-19 [patent_title] => Single chain fusionconstructs comprising multimeric antibody fragments fused to collagen trimerization domains [patent_app_type] => utility [patent_app_number] => 16/060802 [patent_app_country] => US [patent_app_date] => 2016-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 24250 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 238 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16060802 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13440911 [patent_doc_number] => 20180271998 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-27 [patent_title] => DISULFIDE-STABILIZED FABS [patent_app_type] => utility [patent_app_number] => 15/780986 [patent_app_country] => US [patent_app_date] => 2016-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13289 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15780986 [rel_patent_id] =>[rel_patent_doc_number] =>)